Our study was intended to compare anti-epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab with concurrent radiotherapy versus concurrent chemoradiation with weekly cisplatin in loc-regionally advanced HNSCC. Here, EGFR is linked to head and neck squamous cell carcinoma.